Cure8 regulatory brief
A validated human peristaltic intestinal organoid model could make preclinical testing more predictive for drugs affecting gut motility and reduce reliance on animal models.
For people with IBD or other GI motility symptoms, better models may speed discovery of safer, more effective treatments targeted to human biology.
The project also integrates single‑nucleus transcriptomics and high‑content imaging, which could help researchers understand drug mechanisms and identify biomarkers relevant to GI function and toxicity.
Researchers developing GI drugs or models; clinicians and translational scientists interested in GI motility and preclinical tools; patients and advocates tracking advances in IBD and dysmotility research.
This NIH Reporter project describes a Phase I SBIR to develop a scalable human peristaltic intestinal organoid (peristaltic-HIO) platform for drug discovery and preclinical testing of GI motility disorders.
The team plans to validate 96‑well–compatible organoids that show self-organized peristaltic activity and to pair quantitative peristalsis measurements with high‑content imaging and single‑nucleus transcriptomics to create multimodal fingerprints and predictive models.
The write-up outlines two specific aims: (1) engineer and validate peristaltic‑HIOs for scalability and cellular fidelity using design‑of‑experiments and single‑cell/spatial QC, and (2) establish a quantitative, screen‑ready peristalsis assay and benchmark responses to canonical neuromuscular modulators.
At Phase I completion they expect locked manufacturing/QC, a pharmacology reference panel, and an integrated HIO atlas useful for hit identification and lead optimization. This is a project record (funded research) describing planned work and tools rather than reporting clinical results or patient data.
It is useful as a technology development update rather than evidence of clinical benefit.
This is a funded Phase I SBIR project describing planned development and validation work; it does not report clinical trial results. The emphasis is on creating a scalable, assay‑ready human organoid platform and on generating multimodal datasets (imaging plus single‑nucleus sequencing) to support drug screening and predictive modeling.
that technologies in early development often require additional validation and regulatory steps before influencing clinical care.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Center for Advancing Translational Sciences - R43TR006331 - $349,824
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Researchers and clinicians studying Crohn’s disease want to understand whether distinct patient subgroups exist that could affect outcomes or responses. Identifying subpopulations can guide future research into...
At‑home tests that claim to identify food triggers for IBS or related gut conditions may influence how people manage symptoms. Patents covering tests for Crohn’s and ulcerative colitis suggest the company is aiming to...
This study offers a noninflammatory explanation for why many people with Crohn’s continue to have symptoms despite controlled inflammation: sulfur-producing gut microbes and their hydrogen sulfide byproduct. That could...
